Wall Street's Insights Into Key Metrics Ahead of UFP Industries (UFPI) Q1 Earnings
ZACKS· 2025-04-23 14:21
Wall Street analysts expect UFP Industries (UFPI) to post quarterly earnings of $1.59 per share in its upcoming report, which indicates a year-over-year decline of 18.9%. Revenues are expected to be $1.63 billion, down 0.5% from the year-ago quarter.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a company's earnin ...
Unveiling Associated Banc-Corp (ASB) Q1 Outlook: Wall Street Estimates for Key Metrics
ZACKS· 2025-04-23 14:21
Wall Street analysts expect Associated Banc-Corp (ASB) to post quarterly earnings of $0.57 per share in its upcoming report, which indicates a year-over-year increase of 9.6%. Revenues are expected to be $350.71 million, up 7.4% from the year-ago quarter.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Ahead of a company's earnings disclosure, it is cru ...
Gear Up for Alexandria Real Estate Equities (ARE) Q1 Earnings: Wall Street Estimates for Key Metrics
ZACKS· 2025-04-23 14:21
In its upcoming report, Alexandria Real Estate Equities (ARE) is predicted by Wall Street analysts to post quarterly earnings of $2.28 per share, reflecting a decline of 3% compared to the same period last year. Revenues are forecasted to be $758.46 million, representing a year-over-year decrease of 1.4%.The current level reflects a downward revision of 0.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraise ...
What Analyst Projections for Key Metrics Reveal About Crown (CCK) Q1 Earnings
ZACKS· 2025-04-23 14:21
In its upcoming report, Crown Holdings (CCK) is predicted by Wall Street analysts to post quarterly earnings of $1.22 per share, reflecting an increase of 19.6% compared to the same period last year. Revenues are forecasted to be $2.84 billion, representing a year-over-year increase of 2.1%.The consensus EPS estimate for the quarter has been revised 0.1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates d ...
Countdown to Waste Management (WM) Q1 Earnings: Wall Street Forecasts for Key Metrics
ZACKS· 2025-04-23 14:21
Wall Street analysts forecast that Waste Management (WM) will report quarterly earnings of $1.65 per share in its upcoming release, pointing to a year-over-year decline of 5.7%. It is anticipated that revenues will amount to $6.11 billion, exhibiting an increase of 18.4% compared to the year-ago quarter.Over the last 30 days, there has been an upward revision of 0.6% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration ...
Gear Up for Woodward (WWD) Q2 Earnings: Wall Street Estimates for Key Metrics
ZACKS· 2025-04-23 14:21
Wall Street analysts forecast that Woodward (WWD) will report quarterly earnings of $1.44 per share in its upcoming release, pointing to a year-over-year decline of 11.1%. It is anticipated that revenues will amount to $830.26 million, exhibiting a decline of 0.6% compared to the year-ago quarter.Over the last 30 days, there has been an upward revision of 0.4% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of thei ...
Gear Up for Cadence (CDNS) Q1 Earnings: Wall Street Estimates for Key Metrics
ZACKS· 2025-04-23 14:21
In its upcoming report, Cadence Design Systems (CDNS) is predicted by Wall Street analysts to post quarterly earnings of $1.49 per share, reflecting an increase of 27.4% compared to the same period last year. Revenues are forecasted to be $1.24 billion, representing a year-over-year increase of 22.7%.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of th ...
Curious about NXP (NXPI) Q1 Performance? Explore Wall Street Estimates for Key Metrics
ZACKS· 2025-04-23 14:21
Analysts on Wall Street project that NXP Semiconductors (NXPI) will announce quarterly earnings of $2.59 per share in its forthcoming report, representing a decline of 20.1% year over year. Revenues are projected to reach $2.83 billion, declining 9.6% from the same quarter last year.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this ...
Unlocking Q1 Potential of Ameris Bancorp (ABCB): Exploring Wall Street Estimates for Key Metrics
ZACKS· 2025-04-23 14:21
In its upcoming report, Ameris Bancorp (ABCB) is predicted by Wall Street analysts to post quarterly earnings of $1.15 per share, reflecting an increase of 4.6% compared to the same period last year. Revenues are forecasted to be $278.8 million, representing a year-over-year increase of 3.9%.The current level reflects an upward revision of 0.8% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initia ...
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire News Room· 2025-04-23 14:12
SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present updated data from the completed Phase 1 TRAVERSE trial of ALLO-316 in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2 in Chicago, Illinois. The trial e ...